Tumor Biology

, Volume 37, Issue 5, pp 6017–6025 | Cite as

Increased expression of MyD88 and association with paclitaxel resistance in breast cancer

Original Article

Abstract

MyD88 was reported to be associated with paclitaxel sensitivity in lung cancer; however, its roles in breast cancer remain unclear. The objective of this study is to investigate the expression and function of MyD88 in breast cancer. Immunohistochemistry (IHC) was used to analyze the expression of MyD88 in both breast cancer tissues and adjacent normal tissues. Real-time PCR and Western blots were further used to measure the messenger RNA (mRNA) and protein expression. The proliferation was assessed by WST-1. Flow cytometry was used to measure the cell cycle and apoptosis. The transwell assay was used to observe the change of migration and invasion of transfected cells. In breast cancer tissues, the expression of MyD88 was significantly higher than that in tumor-adjacent normal tissues (P < 0.001). MyD88 expression was found to be associated with the differentiation stages (P = 0.019). Kaplan-Meier survival curves showed statistically significant difference on survival in patients with high expression of MyD88 compared with those with normal expression of MyD88 (P = 0.018). Knockdown of MyD88 reduced the proliferation, migration, and invasion of MCF-7 cells and increased the sensitivity of MCF-7 cells to paclitaxel treatment through the inhibition of activation of NF-κB via PI3K/Akt. Our data indicate that MyD88 may be a potential target molecule to be used in diagnosis and treatment of breast cancer.

Keywords

Breast cancer MyD88 Metastasis Paclitaxel Chemoresistance 

Notes

Acknowledgments

This study was supported by grants from the Shanghai Municipal Health Bureau of China (no. 20134274), Shanghai Science and Technology Committee (no. 124119b1602) and Putuo Hospital, Shanghai University of Traditional Chinese Medicine (no. 2013GQ012I).

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Hertz DL, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA. DeesEC.CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Cancer Res Treat. 2012;134(1):401–10.CrossRefGoogle Scholar
  3. 3.
    Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996;2(11):1843–9.PubMedGoogle Scholar
  4. 4.
    Risinger AL, Riffle SM, Lopus M, Jordan MA, Wilson L, Mooberry SL. The taccalonolides and paclitaxel cause distinct effects on microtubule dynamics and aster formation. Mol Cancer. 2014;13:41.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Gehrmann M, Schmidt M, Brase JC, Roos P, Hengstler JG. Prediction of paclitaxel resistance in breast cancer: is CYP1B1*3 a new factor of influence? Pharmacogenomics. 2008;9(7):969–74.CrossRefPubMedGoogle Scholar
  6. 6.
    Jiang YZ, Yu KD, Peng WT, Di GH, Wu J, Liu GY, et al. Enriched variations in TEKT4 and breast cancer resistance to paclitaxel. Nat Commun. 2014;13(5):3802.Google Scholar
  7. 7.
    Coste I, Le Corf K, Kfoury A, Hmitou I, Druillennec S, Hainaut P, et al. Dual function of MyD88 in RAS signaling and inflammation, leading to mouse and human cell transformation. J Clin Invest. 2010;120(10):3663–7.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006;66:3859–68.CrossRefPubMedGoogle Scholar
  9. 9.
    Szajnik M, Szczepanski MJ, Czystowska M, Elishaev E, Mandapathil M, Nowak-Markwitz E, et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene. 2009;28:4353–63.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Wang EL, Qian ZR, Nakasono M, Tanahashi T, Yoshimoto K, Bando Y, et al. High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer. 2010;102:908–15.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Silasi DA, Alvero AB, Illuzzi J, Kelly M, Chen R, Fu HH, et al. MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer. Yale J Biol Med. 2006;79:153–63.PubMedGoogle Scholar
  12. 12.
    Xiang FF, Wu R, Ni ZH, Pan CY, Zhan YP, Xu J, et al. MyD88 expression is associated with paclitaxel resistance in lung cancer A549 cells. Oncol Rep. 2014;32(5):1837–44.PubMedGoogle Scholar
  13. 13.
    Holleman A, Chung I, Olsen RR, Kwak B, Mizokami A, Saijo N, et al. Mir-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene. 2011;30(43):4386–98.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Rincon M, Broadwater G, Harris L, Crocker A, Weaver D, Dressler L, et al. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Res Treat. 2006;100(3):301–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ, et al. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett. 2010;295(1):110–23.CrossRefPubMedGoogle Scholar
  16. 16.
    Kawai T, Akira S. TLR signaling. Cell Death Differ. 2006;13:816–25.CrossRefPubMedGoogle Scholar
  17. 17.
    Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NFkappaB activation by tumour necrosis factor requires the Akt serinethreonine kinase. Nature. 1999;401:82–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Sizemore N, Leung S, Stark GR. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol Cell Biol. 1999;19:4798–805.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Monick MM, Carter AB, Robeff PK, Flaherty DM, Peterson MW, Hunninghake GW. Lipopolysaccharide activates Akt in human alveolar macrophages resulting in nuclear accumulation and transcriptional activity of beta-catenin. J Immunol. 2001;166:4713–20.CrossRefPubMedGoogle Scholar
  20. 20.
    Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A, et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res. 2009;69:3105–13.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Liang BB, Chen R, Wang T, Cao L, Liu YY, Yin F, et al. Myeloid differentiation factor 88 promotes growth and metastasis of human hepatocellular carcinoma. Clin Cancer Res. 2013;19:2905–16.CrossRefPubMedGoogle Scholar
  22. 22.
    Smirnova T, Zhou ZN, Flinn RJ, Wyckoff J, Boimel PJ, Pozzuto M, et al. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. Oncogene. 2012;31(6):706–15.CrossRefPubMedGoogle Scholar
  23. 23.
    Wu H, Windmiller DA, Wang L, Backer JM. YXXM motifs in the PDGF-β receptor serve dual roles as phosphoinositide 3-kinase binding motifs and tyrosine-based endocytic sorting signals. J Biol Chem. 2003;278(42):40425–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Vijapurkar U, Kim MS, Koland JG. Roles of mitogen-activated protein kinase and phosphoinositide 3’-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling. Exp Cell Res. 2003;284:291–302.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Fenfen Xiang
    • 1
  • Zhenhua Ni
    • 2
  • Yueping Zhan
    • 2
  • Qianqian Kong
    • 1
  • Jian Xu
    • 2
  • Jiemin Jiang
    • 1
  • Rong Wu
    • 1
  • Xiangdong Kang
    • 1
  1. 1.Department of Laboratory MedicineShanghai University of Traditional Chinese MedicineShanghaiChina
  2. 2.Central Lab, Putuo HospitalShanghai University of Traditional Chinese MedicineShanghaiChina

Personalised recommendations